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Objectives. Diagnosis of invasive aspergillosis is still disappointing and often delayed because of the lack of
sensitivity of diagnostic tools. DNA detection based-methods have been developed, but differ widely and 
comparisons are difficult to assess. The objective of the study is to compare a new commercial real-time PCR kit, 
affigene® Aspergillus tracer assay, with an in house nested PCR targeting 18S rRNA Aspergillus sp. gene. 
Methods. Twelve patients at risk for invasive aspergillosis were included in the study. They were classified to have 
possible (5 cases), probable (1 case) or proven (6 cases) invasive aspergillosis following E.O.R.T.C. criteria. Fifteen 
serum and respiratory paired samples were collected. The DNA extraction was performed by using the QIAmp DNA 
mini kit® (Qiagen, Germany). All samples were tested by both PCR assays and respiratory samples were cultured. 
Results.  Respiratory samples. A. fumigatus, A. niger and A. flavus were isolated from 10/15 samples; both PCR 
methods were positive for these samples except one that was positive for affigene® and equivocal for the nested 
PCR. The real-time PCR assay reported cycle thresholds ranging from 25 to 38. Three of the five culture-negative 
samples were negative by both PCR methods; one of three was negative in affigene® assay and equivocal by 
nested PCR; the last sample was positive in affigene® assay and negative by nested PCR. Serum. Thirteen of 
fifteen blood samples were negative by both PCR methods. One sample was equivocal by nested PCR and was 
inhibited in affigene® assay despite a culture-positive paired respiratory sample. The last case was inhibited by the 
real-time PCR assay and negative by nested PCR. Nor the nested PCR, nor affigene® assay could detect any 
Aspergillus DNA in serum. In total, there was 87% of agreement between the two PCR assays. 
Conclusion. Both methods are in good agreement and can detect at least three different species of Aspergillus. 
However, the sensitivity of both assays does not permit the detection of Aspergillus DNA in serum. affigene® assay 
can easy replace the “in house” assay: it allows a fast and standardized detection of Aspergillus sp. DNA in 
respiratory samples without inconvenient due to the handling of PCR products.
• Both PCR are in good agreement for the detection of Aspergillus DNA in clinical samples.
• Both PCR assays are able to detect at least three different  Aspergillus species: A. fumigatus, A. 
flavus and A. niger . These tests allow the detection of aspergillosis due to other species than A. 
fumigatus the most frequently targeted species.
• affigene® test is more sensitive to the presence of inhibitors in serum than the conventional test.
• None of these PCR methods could detect Aspergillus DNA in serum even in proved aspergillosis
despite the positivity of the galactomannan detection test. These data suggest that blood sample is 
not an appropriate material to be tested by PCR for the diagnosis of invasive aspergillosis.
• affigene® assay can easy replace the “in house” assay: it allows a fast and standardized detection 
of Aspergillus sp. DNA in respiratory samples including the screening for inhibitors in the same run. 
The real-time technology avoids the inconvenient due to the handling of PCR products and allows 
the implementation of several runs in the same week. The major inconvenient of this method is the 
higher cost in comparison with a “in house” PCR test.
Patients
The study was performed at the University Hospital of Liège from November 2005 to November 
2006. Twelve patients at risk for invasive aspergillosis were included in the study. They were 
classified to have possible (5 cases), probable (1 case) or proven (6 cases) invasive 
aspergillosis following E.O.R.T.C. criteria (1). Fifteen serum and respiratory paired samples 
were collected in total. They were frozen at –20°C until performing the assays.  
Fungal cultures
The cultures were performed on sabouraud agar supplemented with antibiotics (Biomérieux, 
France). The tubes were incubated for 28 days at 30°C.
Galactomannan detection test (Platelia® Aspergillus, Biorad)
The test was performed on serum samples following the manufacturer’s recommendations 
PCR methods
DNA extraction. The DNA extraction was performed by using the QIAmp DNA mini kit® (tissue 
protocol, Qiagen, Germany).  All samples were tested by both PCR assays and respiratory 
samples were cultured. For both serum and respiratory samples, the input volume was 200 µl 
and the elution volume 100 µl.
“In house” PCR. This method is a nested PCR adapted from Yamakami et al. (2). The targeted 
sequence is the 18S rRNA gene of several Aspergillus species.                                              
Briefly, the PCR mixtures were identical for both PCR except for MgCl2. The PCR were carried 
out in a 50-µl volume containing 10 mM Tris-HCl at pH 8.3, 50mM KCl and 1,5 mM MgCl2 (2,25 
mM for the nested PCR) (GeneAmp 10 x PCR buffer II, Applied Biosystems, USA) with 0.4 µM 
of both primers (Eurogentec, Belgium), 2,5 mM dNTP (Promega, The Netherlands), and 1,25 U 
of Taq polymerase (Amplitaq DNA polymerase,  ABI). A 5-µl volume of DNA was added to the 
mixture. Positive and negative controls were amplified in parallel to validate the run. Thermal 
cycling conditions (Thermohydaid, UK) were as follow: 5 min at 94°C; 30 cycles of 1 min at 
94°C, 1 min at 50°C (65°C for the nested PCR) and 1  min at 72°C followed by a final extension 
step of 10 min at 72°C. For the nested PCR, 2 µl of  the first amplified product was added to the 
new reaction mixture.  The final amplified products (357bp) were analyzed on 2% agarose gels 
stained with ethidium bromide and visualized by UV transillumination.  Each sample was 
investigated for the presence of inhibitors by amplification of the ß-globin gene. All samples were 
performed in duplicate. The equivocal results (one positive test, one negative test) were rerun.
affigene® Aspergillus tracer kit
The kit utilizes the real-time PCR technology. All required reagents are included for the 
amplification: a mastermix containing nucleotides, primers/probes, UDG and DNA polymerase in 
a buffered solution. Positive, negative and internal control are also included. 
The amplification has been conducted on the Mx3000PTM instrument (Stratagene, La Jolla, 
USA). The fluorescence was collected in the FAM (targeted gene) and ROX (IC) chanels. The 
results are automatically calculated by a specific software and reported as negative or positive 
(with a Ct value). Only qualitative results are obtained. The run is completed after 2,5 hours.
The kits and the RT-PCR instrument were provided by Sangtec molecular diagnostics.
Diagnosis of invasive aspergillosis is still disappointing and often delayed 
because of the lack of sensitivity of diagnostic tools. Galactomannan
detection in serum is know widely used for the diagnosis of IA in neutropenic
patients with haematological malignancies. DNA detection based-methods 
have been developed, but differ widely for a centre to another and 
comparisons are difficult to assess. 
It is important to develop commercial techniques  in order to develop the use 
of molecular tests by the laboratories involved in the diagnosis of fungal 




• to compare a new commercial real-time PCR kit, affigene®
Aspergillus tracer assay, with an “in house” nested PCR 
targeting 18S rRNA Aspergillus sp. gene
• to evaluate the test feasibility in a routine laboratory practice
Case Underlying Invasive 
"in house" GMc affigene "in house" Fungal affigene aspergillosis
N° disease PCR Antigen PCR PCR culture PCR group
NEG 1,172 NEG NEG NEG NEG
NEG 0,383 NEG NEG NEG NEG
equivocal 1,784 INHb POS A. fumigatus Ct=27
NEG 3,662 NEG NEG NEG NEG
NEG 4,402 NEG POS A. fumigatus Ct=32
3 Lymphoma NEG 0,21 NEG POS A. niger Ct=36 Proved
4 Rheumatoid arthritis NEG 2,021 NEG POS A. fumigatus Ct=30 Probable
5 Myelodysplasia NEG 0,632 NEG POS A. fumigatus Ct=29 possible
6 COPDa  NEG 0,244 INHb equivocal NEG NEG possible
7 Lymphoma NEG 0,576 NEG POS A. flavus Ct=34 possible
8 Tuberculosis NEG 1,734 NEG POS A. fumigatus Ct=25 Proved
9 COPDa  NEG 0,139 NEG POS A. fumigatus Ct=38 possible
10 Lung carcinoma NEG 0,812 NEG POS A. fumigatus Ct=35 possible
11 COPDa  NEG 0,34 NEG equivocal A. fumigatus Ct=38 Proved
12 COPDa  NEG 1,87 NEG NEG NEG Ct=34 Proved






Table 1. Comparison between the « in house » nested PCR and affigene Aspergillus assay.
In total, there was 87% of agreement between the two PCR assays.
P 1869
